[Fundamental evaluation of apolipoprotein B-48 by chemiluminescence enzyme immunoassay--identification of apolipoprotein B-48 with immunoblotting].
BACKGROUND
Apolipoprotein B-48 (apo B-48) is a constituent of chylomicrons and chylomicron remnants, and its fasting concentration has been reported to be a marker of postprandial hyperlipidemia, which is thought to be a risk factor of atherosclerosis.


OBJECTIVE
We evaluated the serum apo B-48 concentrations by chemiluminescence enzyme immunoassay (CLEIA), which was recently introduced as Lumipulse f fully automated immunosaasy analyzer by Fujirebio Inc (Tokyo, Japan), and performed immunoblotting on agarose gel electrophoresis with anti-apo B-48 antibody.


RESULTS
Apo B-48 assay was intra-assay reproducible (CVs: 1.9-3.1%) and inter-assay reproducible (CVs: 2.2-4.4%). The assay range for apo B-48 was from 0.2 to 40.0 microg/ml. The effects of interfering substances such as free/conjugated birirubin, hemoglobin, Intrafat, ascorbic acid and rheumatoid factor were negligible. For storage, it was preferable to freeze, and to avoid frozen-thaw process as much as possible. Anti-apo B-48 antibody was reactive over a wide range from origin to the position of very-low-density lipoproteins in immunoblotting after agarose gel electrophoresis.


CONCLUSIONS
Apo B-48 measurement by CLEIA was feasible to clinical use for the assessment of lipoprotein metabolism.
Department of Clinical Laboratory, Kobe University Hospital, Kobe.
Itsuko
I
Sato
Yoshio
Y
Fujioka
Fujio
F
Hayashi
Masahiko
M
Mukai
Seiji
S
Kawano
Yuichi
Y
Ishikawa
Shizuya
S
Yamashita
Shunichi
S
Kumagai
D053283:Apolipoprotein B-48 / Q000097:blood* / Q000302:isolation & purification*; D050197:Atherosclerosis / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques / Q000379:methods*; D008074:Lipoproteins / Q000378:metabolism; D012307:Risk Factors
D053283:Apolipoprotein B-48; D015415:Biomarkers; D008074:Lipoproteins